Cagrilintide — Long-Acting Amylin Analogue (Research Evidence Summary)
Research evidence summary
also known as AM833, NNC0174-0833
Cagrilintide is a once-weekly amylin analogue from Novo Nordisk. Trials of cagrilintide alone and with semaglutide (CagriSema), doses studied, risks and unknowns.
- Sequence
- Lipidated, long-acting analogue of human amylin
- MW
- 4409 Da (PubChem)
- Receptor
- Amylin receptor (cagrilintide is an amylin analogue)
- Half-life
- 6.6 to 8.1 days (159 to 195 hours) in a phase 1b trial in adults with overweight or obesity, measured with semaglutide given alongside PubMed 33894838
Quoted from the source
Cagrilintide 0·16-4·5 mg had a half-life of 159-195 h, with a median tmax of 24-72 h.
- Routes in study
- SC
What is cagrilintide?
Cagrilintide (development codes AM833 and NNC0174-0833) is a lipidated, long-acting analogue of amylin, a pancreatic hormone that induces satiety (PMID 34288673; PMID 34798060). A 2021 chemistry paper says native amylin readily forms amyloid fibrils, which makes it hard to develop as a drug (PMID 34288673).
Cagrilintide is not a GLP-1 agonist. CagriSema is a once-weekly combination of cagrilintide with semaglutide, a GLP-1 receptor agonist (PMID 42251860). In a phase 1b trial the half-life of cagrilintide was 159 to 195 hours (about 6.6 to 8.1 days), measured with semaglutide given alongside (PMID 33894838).
What has been studied
All doses below are subcutaneous and once weekly, except daily liraglutide in the first row.
| Study | Dose and length | Who | Main result |
|---|---|---|---|
| Phase 2, dose-finding (PMID 34798060) | Cagrilintide 0.3, 0.6, 1.2, 2.4 or 4.5 mg, liraglutide 3.0 mg daily, or placebo; 26 weeks including up to 6 weeks of escalation | 706 adults without diabetes: 100 to 102 on each cagrilintide dose, 99 on liraglutide and 101 on placebo | Weight fell 6.0% to 10.8% across cagrilintide doses against 3.0% on placebo (assuming adherence to treatment). At 4.5 mg the fall was 10.8% against 9.0% on liraglutide. Gastrointestinal events 41% to 63% against 32% on placebo; nausea 20% to 47% against 18%. |
| Phase 2, type 2 diabetes (PMID 37364590) | CagriSema, semaglutide 2.4 mg or cagrilintide 2.4 mg alone, 32 weeks | 92 adults with type 2 diabetes (31, 31 and 30) | HbA1c (a blood test of average glucose) fell 2.2 percentage points on CagriSema, 1.8 on semaglutide and 0.9 on cagrilintide alone. Weight fell 15.6%, 5.1% and 8.1%. Adverse events in 68%, 71% and 80%. |
| Phase 1b (PMID 33894838) | Cagrilintide 0.16 to 4.5 mg with semaglutide 2.4 mg, up to 20 weeks | 95 adults aged 18 to 55 exposed to treatment | Cagrilintide exposure rose in proportion to dose and did not affect semaglutide exposure. Adverse events in 97% on cagrilintide and 96% on placebo, mostly mild to moderate. |
| REDEFINE 1, phase 3 (PMID 40544433) | CagriSema, semaglutide 2.4 mg alone, cagrilintide 2.4 mg alone or placebo, 68 weeks | 3,417 adults with obesity, no diabetes (2,108, 302, 302 and 705) | CagriSema: weight fell 20.4% against 3.0% on placebo. Gastrointestinal events 79.6% against 39.9%. In a later paper summarising the trial, the cagrilintide-alone arm lost 11.8%, semaglutide 16.1%, CagriSema 22.7% and placebo 2.3% (PMID 41328546). |
| REDEFINE 2, phase 3 (PMID 40544432) | CagriSema 2.4 mg of each, or placebo, 68 weeks | 1,206 adults with type 2 diabetes and BMI 27 or more | Weight fell 13.7% against 3.4% on placebo. Gastrointestinal events 72.5% against 34.4%. No cagrilintide-alone arm. |
| REIMAGINE 2, phase 3 (PMID 42251859) | CagriSema at 2.4 mg or 1.0 mg of each, semaglutide 2.4 or 1.0 mg, cagrilintide 2.4 mg alone, or placebo, 68 weeks | 2,713 adults with type 2 diabetes on metformin, with or without an SGLT2 inhibitor (a type of diabetes tablet); 152 on cagrilintide alone | Primary comparison was CagriSema against semaglutide 2.4 mg: HbA1c fell 1.91 against 1.75 percentage points. Adverse events in 82.2% of the cagrilintide-alone group and 70.5% on placebo. The abstract does not report an efficacy result for the cagrilintide-alone arm. |
| REIMAGINE 1 and 3, phase 3 (PMID 42251860; PMID 42251856) | CagriSema at 2.4 mg or 1.0 mg of each, or placebo, 40 weeks | 189 adults with type 2 diabetes not controlled by diet and exercise (REIMAGINE 1); 274 on basal insulin (REIMAGINE 3) | HbA1c fell 1.8 (2.4 mg) and 1.5 (1.0 mg) against 0.1 on placebo in REIMAGINE 1, with weight down 13.8% and 11.8% against 1.4%; 2.33 and 2.10 against 0.66 in REIMAGINE 3, which reports one death (1.0 mg group), from malignancy and not related to treatment. Neither has a cagrilintide-alone arm. |
The REIMAGINE 2 paper has a published erratum (Lancet Diabetes and Endocrinology 2026;14(8):e11); any REIMAGINE 2 figure above (HbA1c change, adverse-event proportions, group sizes) may differ from the corrected paper. A sub-analysis of REDEFINE 1 reported systolic blood pressure falling 10.9 mm Hg on CagriSema against 2.8 on placebo; it analysed the CagriSema and placebo groups, not cagrilintide alone (PMID 41328546).
Escalation. The phase 2 abstract gives no step doses or lengths beyond up to 6 weeks of escalation. In the phase 1b trial, cagrilintide and semaglutide were co-escalated "in 4-week intervals to the desired dose over 16 weeks" (PMID 33894838). The REDEFINE 1 registry record lists a 16-week escalation (ClinicalTrials.gov NCT05567796), without step doses.
Registry results. ClinicalTrials.gov has posted results for the phase 2 trial (NCT03856047) and the phase 2 diabetes trial (NCT04982575). In the phase 2 trial serious adverse events were listed for 6 of 101 on 0.3 mg, 2 of 100 on 0.6 mg, 7 of 102 on 1.2 mg, 3 of 102 on 2.4 mg, 4 of 101 on 4.5 mg, 4 of 99 on liraglutide and 3 of 101 on pooled placebo, with no deaths. In the diabetes trial they were listed for 4 of 30 on cagrilintide alone, 0 of 31 on CagriSema and 2 of 31 on semaglutide. REDEFINE 1 (NCT05567796) and REDEFINE 2 (NCT05394519) had no posted results on 6 November 2026.
Risks and unknowns
- Gastrointestinal events were the most frequent adverse events in the phase 2 trial, together with administration-site reactions (PMID 34798060). In REDEFINE 1 and 2 (rates in the table) the abstracts describe them as mostly transient and mild to moderate (PMID 40544433; PMID 40544432).
- Stopping treatment. In the phase 2 trial, 10% of participants permanently discontinued treatment, which the abstract attributes mostly to adverse events (30 participants, 4%) (PMID 34798060).
- Cagrilintide alone. The later paper summarising REDEFINE 1 does not say which analysis its figures use (11.8% for cagrilintide alone, 22.7% for CagriSema); the main paper's primary treatment-policy figures are 20.4% and 3.0% (PMID 41328546). Most phase 3 results are for CagriSema, which does not separate out what cagrilintide adds. A 2026 meta-analysis that pooled the cagrilintide-alone groups of two trials (Lau 2021 and Garvey 2025) reported a mean body-weight difference of 6.08% against placebo (95% confidence interval 4.14 to 8.02), with substantial heterogeneity (I² = 89%, meaning the trials' results differed widely), without meaningful HbA1c improvement, and "modest but statistically significant increases in adverse events" (PMID 42583410).
- Added effect. In the phase 2 diabetes trial the HbA1c difference between CagriSema and semaglutide alone was not significant (p=0.075), while weight loss was greater than on either alone (PMID 37364590). In REIMAGINE 2, CagriSema lowered HbA1c by 0.16 percentage points more than semaglutide 2.4 mg (PMID 42251859).
- Duration. The main treatment periods in the trials above were up to 68 weeks. Effects beyond that are unknown.
UK regulatory position
This site gives no legal advice or sourcing information and does not sell anything. Rules on unauthorised medicines exist in the Human Medicines Regulations 2012. Whether a particular product is a medicinal product under regulation 2 depends on its specifics, including how it is presented and how it functions. For questions about medicines speak to a GP or pharmacist; problems with a medicine can be reported to the MHRA through the Yellow Card scheme.
In the US, a DailyMed search for "cagrilintide" and for "CagriSema" on 6 November 2026 returned no entries, and an openFDA search for the substance name "cagrilintide" returned no record.
Related pages
- Semaglutide monograph, the GLP-1 arm of CagriSema
- Tirzepatide monograph, a dual GIP/GLP-1 agonist
- Tirzepatide vs cagrilintide
- CagriSema evidence review
- GLP-1 and incretin research hub
Regulatory and clinical status
UK status: Investigational (Novo Nordisk). A DailyMed search for cagrilintide and for CagriSema, and an openFDA search for cagrilintide, on 6 November 2026 found no label.
Read what UK official sources say about medicines in our UK regulation hub and our explanation of why “research grade” does not mean safe. PeptideStacks does not make editorial sourcing recommendations within research content; any vendor links elsewhere on this page appear in a clearly-labelled sponsor block (see our conflict-of-interest disclosure).
References
Peer-reviewed sources for the claims above. Where an editor has verified study type, sample size, outcome and limitation, the citation is rendered as a card; otherwise as a plain reference. Links open PubMed or the journal DOI.
- Lau DCW, Erichsen L, Francisco AM, et al.. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet. 2021;398(10317) :2160-2172 doi:10.1016/S0140-6736(21)01751-7 · PMID: 34798060
- Enebo LB, Berthelsen KK, Kankam M, et al.. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial. Lancet. 2021;397(10286) :1736-1748 doi:10.1016/S0140-6736(21)00845-X · PMID: 33894838
- Frias JP, Deenadayalan S, Erichsen L, et al.. Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. Lancet. 2023;402(10403) :720-730 doi:10.1016/S0140-6736(23)01163-7 · PMID: 37364590
- Garvey WT, Blüher M, Osorto Contreras CK, et al.. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2025;393(7) :635-647 doi:10.1056/NEJMoa2502081 · PMID: 40544433
- Davies MJ, Bajaj HS, Broholm C, et al.. Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. New England Journal of Medicine. 2025;393(7) :648-659 doi:10.1056/NEJMoa2502082 · PMID: 40544432
- Verma S, Böttcher M, Brown P, et al.. CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1. Hypertension. 2026;83(2) :e26055 doi:10.1161/HYPERTENSIONAHA.125.26055 · PMID: 41328546
- Aroda VR, Buzzetti R, Dalskov SM, et al.. Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study. Lancet Diabetes & Endocrinology. 2026;14(8) :649-661 doi:10.1016/S2213-8587(26)00126-9 · PMID: 42251860
- Buse JB, Bajaj HS, Dalskov SM, et al.. Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study. Lancet Diabetes & Endocrinology. 2026;14(8) :662-677 doi:10.1016/S2213-8587(26)00125-7 · PMID: 42251859
- Rosenstock J, Billings LK, Gajria R, et al.. Cagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study. Lancet. 2026;408(10549) :38-51 doi:10.1016/S0140-6736(26)01022-6 · PMID: 42251856
- Kruse T, Hansen JL, Dahl K, et al.. Development of Cagrilintide, a Long-Acting Amylin Analogue. Journal of Medicinal Chemistry. 2021;64(15) :11183-11194 doi:10.1021/acs.jmedchem.1c00565 · PMID: 34288673
- Yaseen M, Ameer A, Ali Z, et al.. Amylin-based obesity therapy: a meta-analysis of Cagrilintide and CagriSema versus placebo. Annals of Medicine and Surgery. 2026;88(8) :5317-5326 doi:10.1097/MS9.0000000000005353 · PMID: 42583410
- Correction (2026-11-06): Corrected 6 November 2026 after a dose and citation audit: the claim that cagrilintide alone has no phase 3 support was wrong and was corrected; an unsourced discovery date was removed; the half-life was restated from the paper; legal text was replaced.
If you spot an error or have new evidence to suggest, please use our corrections policy.
Research combinations referencing Cagrilintide
Combination evidence reviews on this site that include Cagrilintide as one of their peptides.
Continue reading
Retatrutide — Triple GIP/GLP-1/Glucagon Receptor Agonist
Retatrutide (LY3437943) is an investigational once-weekly GIP, GLP-1 and glucagon receptor agonist. Phase 2 and phase 3 results, doses studied, risks and unknowns.
Semaglutide — GLP-1 Receptor Agonist (Research Evidence Summary)
Semaglutide is a GLP-1 receptor agonist sold as Wegovy, Ozempic and Rybelsus. Label doses and limits, trial results, the thyroid boxed warning and other risks.
Tirzepatide vs Cagrilintide — Incretin vs Amylin Approach to Weight Reduction
Tirzepatide (GIP/GLP-1 agonist, on the MHRA list of licensed GLP-1 medicines) compared with cagrilintide (amylin analogue, investigational): trials, risks and what has not been compared.